Lupin has bagged the approval for Lenalidomide capsules. This drug is used in the treatment of Multiple Myeloma (MM). In an exchange filing, the company announced that it has received approval for its ...

Lupin shares have gained for eight consecutive trading sessions as of Tuesday's close. The last time the stock gained for eight consecutive sessions was between December 23, 2024 to January 1, 2025.

This comes just weeks after Lupin secured USFDA approval for its Risperidone Injectable, used to treat schizophrenia and ...

The capsules will be available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths and are bioequivalent to REVLIMID(R) capsules of Bristol-Myers Squibb Company. The product will be manufactured ...

Lupin’s shares rose 2.8% in afternoon trading after the company received a key U.S. Food and Drug Administration (FDA) ...

Drugmaker Lupin said it has received the USFDA's approval for Risperidone for extended-release injectable suspension ...

Mumbai: Lupin has announced that the U.S. Food and Drugs Administration (USFDA) has closed the inspection with six ...

Lupin Manufacturing Solutions has announced that Empagliflozin API, manufactured at its Vizag facility, has received CADIFA ...

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator for its generic version of ...

Indias top drugmakers, Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN), are moving closer to developing ...